The combination of serum miR‐96‐5p and CTSB represents potential serum biomarkers for cognitive impairment, and targeting the neuronal miR‐96‐5p/CTSB pathway may serve as a promising therapeutic strategy for AD. This evidence concerns the gene CTSB and Cognitive impairment.